可切除的局部进展期胃癌及转移性胃癌治疗现状及进展  

Status and progress in the treatment for locally resectable progressive gastric cancer and metastatic gastric cancer

作　　者：廖孝枫 刘合利[1] 刘鹏[1] LIAO Xiaofeng;LIU Heli;LIU Peng(Department of Gastrointestinal Surgery,Xiangya Hospital,Central South University,Changsha 410008;Department of Gastrointestinal and Pancreatic Surgery,Nanjing Jiangning Hospital,Nanjing 211100,China)

机构地区：[1]中南大学湘雅医院胃肠外科,长沙410008 [2]南京市江宁医院胃肠胰外科,南京211100

出　　处：《中南大学学报（医学版）》2020年第4期426-434,共9页Journal of Central South University ：Medical Science

基　　金：湖南省科技厅重点资助项目(2014SK2012)。

摘　　要：对于可切除胃癌而言,根治性手术仍然作为治疗的核心手段,但对于转移性胃癌而言,手术方式的选择和手术效果需要探索。放射治疗(以下简称放疗)、化学治疗(以下简称化疗)、分子靶向治疗在延长胃癌患者生存期中发挥了重要的作用,术后放疗、化疗可以延长生存期,对于局部晚期的胃癌患者,术前行放疗、化疗相比于直接手术,亦能进一步延长患者的生存期。另外,随着分子靶向药物(如抗血管生成药物、免疫抑制药物等)的研发和使用,胃癌患者的生存期可进一步延长。For resectable gastric cancer,although radical surgery is still the main treatment,methods of operation and the curative effect of operation are still in the stage of exploration for metastatic gastric cancer.Radiotherapy,chemotherapy and molecular targeted therapy also play an important role in prolonging the survival period of patients with gastric cancer.Postoperative radiotherapy and chemotherapy can prolong the survival time,but for patients with locally advanced gastric cancer,the preoperative radiotherapy and chemotherapy can also further improve the survival period of patients compared with direct operation.In addition,with the development and using of molecular targeted drugs,such as antiangiogenic agents,immunosuppressive drugs and so on,the survival period of patients with gastric cancer has been further extended.

关 键 词：进展期胃癌 转移性胃癌 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]